Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 36% Improvement Relative Risk HCQ for COVID-19  Gómez et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 1,799 patients in Spain (March - October 2020) Lower mortality with HCQ (p<0.000001) Gómez et al., Medicina Clínica, October 2022 Favors HCQ Favors control

Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry

Gómez et al., Medicina Clínica (English Edition), doi:10.1016/j.medcle.2022.01.020
Oct 2022  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 1,799 hospitalized COVID-19 patients with atrial fibrillation in Spain, showing lower mortality with HCQ treatment in unadjusted results.
This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 35.8% lower, RR 0.64, p < 0.001, treatment 500 of 1,378 (36.3%), control 238 of 421 (56.5%), NNT 4.9.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gómez et al., 13 Oct 2022, retrospective, Spain, peer-reviewed, 10 authors, study period 1 March, 2020 - 1 October, 2020. Contact:
This PaperHCQAll
Mortality risk factors in patients with SARS-CoV-2 infection and atrial fibrillation: Data from the SEMI-COVID-19 registry
MD Javier Azaña Gómez, MD, PhD2 Luis M Pérez-Belmonte, Manuel Rubio-Rivas, José Bascuñana, Raúl Quirós-López, María Luisa Taboada Martínez, Esther Montero Hernandez, Fernando Roque-Rojas, Manuel Méndez-Bailón, MD, PhD1 ¶ Ricardo Gómez-Huelgas
Medicina Clínica (English Edition), doi:10.1016/j.medcle.2022.01.020
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of interests The authors state that they have no conflict of interest in relation to this publication. J o u r n a l P r e -p r o o f Appendix B [{(Annex)}]Additional material Additional material to this article can be found in the electronic version available at doi:10.1016/j.medcli.2022.01.008. Appendix C [{(Annex)}]Additional material mmc1
Al-Abbas, Alshaikhli, Amran, New-Onset Atrial Fibrillation and Multiple Systemic Emboli in a COVID-19 Patient, Cureus
Alonso Gisbert, Blázquez Llistosella, Casanova, García Flores, Hinojo et al., Salnes Hospital (Villagarcia de Arosa
Aparicio, Bernabeu-Wittel, Suárez, Nieto, Miranda et al., Public Hospital of Monforte de Lemos
Baena-Díez, Grau, Forés, Fernández-Bergés, Elosua et al., estudio DARIOS. Prevalence of atrial fibrillation and its associated factors in Spain: An analysis of 6 population-based studies. DARIOS Study, Rev Esp Cardiol (Engl Ed)
Casas-Rojo, Santos, Millán-Núñez-Cortés, Lumbreras-Bermejo, Ramos-Rincón et al., del Grupo SEMI-COVID-19 Network. Clinical characteristics of patients hospitalized with COVID-19 in Spain: Results from the SEMI-COVID-19 Registry, Rev Clin Esp (Barc)
Díez-Villanueva, Alfonso, Charlson, Feinstein, A new clinical index of growth rate in the staging of breast cancer, Journal of Geriatric Cardiology: JGC, doi:10.11909/j.issn.1671-5411.2019.01.00517
Ena, Enrique, Segado, Defense General Hospital
Esther, Espartero, Rivas, De La Sierra Navas Alcántara, Tirado-Miranda, None
Gawałko, Kapłon-Cieślicka, Hohl, Dobrev, Linz, COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications, Int J Cardiol Heart Vasc
Gracia Gutiérrez, Esther, Trallero, None
Gómez-Doblas, Muñiz, Martin, Rodríguez-Roca, Lobos et al., Prevalence of atrial fibrillation in Spain. OFRECE study results, Rev Esp Cardiol (Engl Ed)
Harrison, Fazio-Eynullayeva, Lane, Underhill, Lip, Atrial fibrillation and the risk of 30-day incident thromboembolic events, and mortality in adults ≥ 50 years with COVID-19, J Arrhythm
Hope Covid-, Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry, Rev Esp Cardiol
J O U R N A L P R E, -p r o o f
José, Castro, Lorenzo López Reboiro, González, Marina Baixa Hospital
Kohli, Meinert, Chong, Tesher, Fulminant myocarditis and atrial fibrillation in child with acute COVID-19, J Electrocardiol
Lawler, Goligher, Berger, Neal, Mcverry et al., Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19, N Engl J Med
María, Claudio, Barreales Rodríguez, Muñoz, Pérez et al., Virgen del Rocío University Hospital
Musikantow, Turagam, Sartori, Chu, Kawamura et al., Atrial Fibrillation in Patients Hospitalized With COVID-19: Incidence, Predictors, Outcomes, and Comparison to Influenza, JACC Clin Electrophysiol
Nadkarni, Bagiella, Chang, Moreno, Pujadas, Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19, J Am Coll Cardiol
Pardo Sanz, Tahoces, Pérez, Ferrer, Recalde et al., New-onset atrial fibrillation during COVID-19 infection predicts poor prognosis, Cardiol J
Ramos-Rincon, Buonaiuto, Ricci, Martín-Carmona, Paredes-Ruíz et al., Clinical Characteristics and Risk Factors for Mortality in Very Old Patients Hospitalized With COVID-19 in Spain, J Gerontol A Biol Sci Med Sci
Sattar, Connerney, Ullah, Philippou, Slack et al., COVID-19 Presenting as Takotsubo Cardiomyopathy Complicated with Atrial Fibrillation, Int J Cardiol Heart Vasc
Tomaszuk-Kazberuk, Koziński, Domienik-Karłowicz, Jaguszewski, Darocha et al., Pharmacotherapy of atrial fibrillation in COVID-19 patients, Cardiol J
Uribarri, Núñez-Gil, Aparisi, Arroyo-Espliguero, Eid et al., None
Vanesa, Castro, María, Lomba, Aparicio et al., e -p r o o f References BIBLIOGRAFÍA
Vasco, Santacruz, Valverde Muñoz, Blanes Regional Hospital
Wallentin, Lindbäck, Eriksson, Hijazi, Eikelboom et al., Angiotensinconverting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation, Eur Heart J
Álvarez Díaz, López, Martul Pego, Pérez, Ferro et al., None
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop